FDA Approves Gardasil 9 For Prevention Of Certain Cancers

FDA Approves Gardasil 9 For Prevention Of Certain Cancers
(Image source)
The U.S. Food and Drug Administration has approved Gardasil 9 for the prevention of certain diseases caused by nine types of Human Papillomavirus (HPV). Covering nine HPV types, five more HPV types than the previous Gardasil, Gardasil 9 has the potential to prevent approximately 90 percent of cervical, vulvar, vaginal and anal cancers.
 
Gardasil 9 is a vaccine approved for use in females ages 9 through 26 and males ages 9 through 15. It is approved for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV types 6 or 11. Gardasil 9 adds protection against five additional HPV types, which cause approximately 20 percent of cervical cancers and are not covered by previously FDA-approved HPV vaccines.
 
Gardasil 9 is administered as three separate shots, with the initial dose followed by additional shots given two and six months later. For all of the indications for use approved by the FDA, Gardasil 9’s full potential for benefit is obtained by those who are vaccinated prior to becoming infected with the HPV strains covered by the vaccine. The safety of Gardasil 9 was evaluated in approximately 13,000 males and females, and the most commonly reported adverse reactions were injection site pain, swelling, redness, and headaches. 

(Source)